NCT00555919View on ClinicalTrials.gov

ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

March 31, 2011

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Lonaprisan (ZK 230211, BAY86-5044)

25 mg daily oral treatment

DRUG

Lonaprisan (ZK 230211, BAY86-5044)

100 mg daily oral treatment

Trial Locations (28)

1100

Vienna

5020

Salzburg

6020

Innsbruck

8036

Graz

9007

Sankt Gallen

18059

Rostock

20089

Rozzano

24105

Kiel

28040

Madrid

34000

Montpellier

44805

Nantes

51056

Reims

59020

Lille

60590

Frankfurt am Main

65130

Vaasa

69008

Lyon

72076

Tübingen

75020

Paris

91054

Erlangen

FIN-20521

Turku

15-540

Bialystok

80-219

Gdansk

10-226

Olsztyn

60-569

Poznan

413 45

Gothenburg

851 86

Sundsvall

351 85

Vaxjo

NG5 1PB

Nottingham

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY